CD200 and neoplasm: Extending findings observed in rodent models which demonstrated that administration of a CD200 peptide inhibitor overcomes immune tolerance induced by tumor vaccination by increasing leukocyte infiltration into the vaccine site, bolstering cytokine and chemokine production, and enhancing tumor cytolytic activity, this approach was recently evaluted in dogs with high-grade gliomas (209).